RxDoctor Payments Data
★ My doctorsLook up a doctor →

Daniel Rees, MD

Critical Care Medicine · Baton Rouge, LANPI 1780094011

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 186 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 12.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,169 and has fallen 62.8% since, to $435 in 2025.

$3,826in general payments, 2019–2025

Across 186 payments — averaging $20.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$493
  • AstraZeneca$417
  • Regeneron Healthcare Solutions, Inc.$348
  • Pfizer$266
  • Baxter Healthcare$263
  • Actelion Pharmaceuticals US, Inc.$178
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$3,826100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim25$493
AstraZeneca(2 entities)25$417
Regeneron Healthcare Solutions, Inc.12$348
Pfizer17$266
Baxter Healthcare8$263
Actelion Pharmaceuticals US, Inc.8$178
United Therapeutics Corporation7$165
Grifols USA, LLC6$158
Merck8$156
Abiomed2$154
GSK7$134
UCB, Inc.8$129
Mallinckrodt Hospital Products Inc.6$126
Electromed, Inc.10$87
Inogen, Inc.6$86
Sanofi3$74
Mylan Specialty L.p.3$68
Johnson & Johnson3$65
Astellas Pharma US Inc3$59
Coaptech, Inc.1$44
Shionogi Inc2$43
Verona Pharma, Inc.2$43
Paratek Pharmaceuticals, Inc.2$42
La Jolla Pharmaceutical Company2$41
Vifor Pharma, Inc.2$33
Otsuka America Pharmaceutical, Inc.2$32
Cleerly, Inc.1$27
Vapotherm Inc1$24
Chiesi USA, Inc.1$20
Amgen1$19
Liquidia Technologies, Inc.1$18
Bard Peripheral Vascular, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,826 in reported general payments places this provider in the 75th percentile of 72 critical care medicine providers in Louisiana.

See all critical care medicine providers in Louisiana →

Medicare billing

Part B allowed, 2024
$24,983
Medicare patients
86
Services billed
157

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other critical care medicine in Baton Rouge

See the full list for Louisiana →

Where these figures come from

Is this you, or does something look wrong? →